A Cost Analysis of Gyrase A Testing and Targeted Ciprofloxacin Therapy Versus Recommended 2-Drug Therapy for Neisseria gonorrhoeae Infection
dc.contributor.author | Allan-Blitz, Lao-Tzu | * |
dc.contributor.author | Hemarajata, Peera | * |
dc.contributor.author | Humphries, Romney M. | * |
dc.contributor.author | Wynn, Adriane | * |
dc.contributor.author | Segura, Eddy R. | * |
dc.contributor.author | Klausner, Jeffrey D. | * |
dc.date.accessioned | 2018-02-12T14:44:00Z | |
dc.date.available | 2018-02-12T14:44:00Z | |
dc.date.issued | 2018-02 | |
dc.identifier.citation | A Cost Analysis of Gyrase A Testing and Targeted Ciprofloxacin Therapy Versus Recommended 2-Drug Therapy for Neisseria gonorrhoeae Infection 2018, 45 (2):87 Sexually Transmitted Diseases | es |
dc.identifier.issn | 0148-5717 | |
dc.identifier.doi | 10.1097/OLQ.0000000000000698 | |
dc.identifier.uri | http://hdl.handle.net/10757/622635 | |
dc.description | El texto completo de este trabajo no está disponible en el Repositorio Académico UPC por restricciones de la casa editorial donde ha sido publicado. | es |
dc.description.abstract | From the *Division of Infectious Diseases, Department of Medicine, †Department of Laboratory Medicine, David Geffen School of Medicine, Department of Medicine, ‡Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA; §Escuela de Medicina, Universidad Peruana de Ciencias Aplicadas, Lima, Peru; and ¶Division of Infectious Diseases, Department of Medicine, University of California Los Angeles, Los Angeles, CA Conflict of Interest and Sources of Funding: None declared. This research was supported by the United States National Institutes of Health grants R21AI117256 and R21AI109005 as well as the South American Program in HIV Prevention Research NIH/NIMH R25MH087222. Correspondence: Lao-Tzu Allan-Blitz, MD Candidate, 2018, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Ave, Los Angeles, CA 90095. E‐mail: [email protected]. Received for publication February 21, 2017, and accepted July 30, 2017. DOI: 10.1097/OLQ.0000000000000698 | |
dc.format | application/pdf | es |
dc.language.iso | eng | es |
dc.publisher | Lippincott Williams and Wilkins | es |
dc.relation.url | http://Insights.ovid.com/crossref?an=00007435-201802000-00004 | es |
dc.rights | info:eu-repo/semantics/restrictedAccess | es |
dc.subject | Azithromycin | es |
dc.subject | Ceftriaxone | es |
dc.subject | Ciprofloxacin | es |
dc.subject | DNA topoisomerase (ATP hydrolysing) A | es |
dc.subject | Antibiotic resistance | es |
dc.subject | Antibiotic sensitivity | es |
dc.subject | Chlamydiasis | es |
dc.subject | Cost benefit analysis | es |
dc.title | A Cost Analysis of Gyrase A Testing and Targeted Ciprofloxacin Therapy Versus Recommended 2-Drug Therapy for Neisseria gonorrhoeae Infection | es |
dc.type | info:eu-repo/semantics/article | es |
dc.identifier.journal | Sexually Transmitted Diseases | es |
dc.description.funding | From the *Division of Infectious Diseases, Department of Medicine, †Department of Laboratory Medicine, David Geffen School of Medicine, Department of Medicine, ‡Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA; §Escuela de Medicina, Universidad Peruana de Ciencias Aplicadas, Lima, Peru; and ¶Division of Infectious Diseases, Department of Medicine, University of California Los Angeles, Los Angeles, CA Conflict of Interest and Sources of Funding: None declared. This research was supported by the United States National Institutes of Health grants R21AI117256 and R21AI109005 as well as the South American Program in HIV Prevention Research NIH/NIMH R25MH087222. Correspondence: Lao-Tzu Allan-Blitz, MD Candidate, 2018, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Ave, Los Angeles, CA 90095 | es_PE |
dc.description.peerreview | Revisión por pares | es_PE |
refterms.dateFOA | 2018-06-15T22:11:39Z | |
html.description.abstract | From the *Division of Infectious Diseases, Department of Medicine, †Department of Laboratory Medicine, David Geffen School of Medicine, Department of Medicine, ‡Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA; §Escuela de Medicina, Universidad Peruana de Ciencias Aplicadas, Lima, Peru; and ¶Division of Infectious Diseases, Department of Medicine, University of California Los Angeles, Los Angeles, CA Conflict of Interest and Sources of Funding: None declared. This research was supported by the United States National Institutes of Health grants R21AI117256 and R21AI109005 as well as the South American Program in HIV Prevention Research NIH/NIMH R25MH087222. Correspondence: Lao-Tzu Allan-Blitz, MD Candidate, 2018, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Ave, Los Angeles, CA 90095. E‐mail: [email protected]. Received for publication February 21, 2017, and accepted July 30, 2017. DOI: 10.1097/OLQ.0000000000000698 |
Files in this item
This item appears in the following Collection(s)
-
Medicina [970]